A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit the Mcl-1 protein—an essential survival factor for therapy-resistant ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

A new study published in the journal of Biomarkers in Medicine showed that the development of new-onset cancer is ...

Cancer researchers have long treated genetic chaos and epigenetic rewiring as separate engines of disease, two parallel ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...

Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...

The team of researchers led by the IIT Madras has developed a cutting-edge nanoinjection drug delivery platform that can make breast cancer treatment safer ...

Targeting SUMOylation in glioblastoma opens new avenue for therapeutic interventions and biomarker discovery Glioblastoma, a ...

Researchers from the Indian Institute of Technology-Madras (IIT-Madras), in collaboration with Monash University and Deakin University in Australia, have developed an innovative <br />cutting-edge ...

The report concludes that BPC-157 remains an active area of scientific inquiry within orthopedic research, gastrointestinal integrity studies, and neurological tissue repair models. The publication ...

The combination of trabectedin (Yondelis; Pharma Mar, Johnson & Johnson) and olaparib (Lynparza; AstraZeneca, Merck) may be a meaningful treatment for certain patients with advanced soft tissue ...